Fetal Supraventricular Tachycardia: What the Adult Cardiologist Needs to Know

Sutopa Purkayastha, Michael Weinreich, Joao D. Fontes, Joe F. Lau, Diana S. Wolfe, Anna E. Bortnick

Research output: Contribution to journalReview articlepeer-review

Abstract

Fetal supraventricular tachycardia management is challenging, with consequences for both the fetus and the mother. If left untreated, fetal hydrops may ensue, at which point delivery and treatment of the arrhythmia is preferred. However, if the fetus is not at term nor near-term, significant doses of antiarrhythmics may be needed to achieve adequate transplacental bioavailability. Although digoxin has classically been the mainstay of treatment, the use of flecainide or sotalol as monotherapy or in combination with digoxin is being studied. Interdisciplinary team management and shared decision-making between the physician and patient are key to achieving successful outcomes. Adult cardiologists, particularly inpatient consultation services or through burgeoning cardio-obstetrics programs, may, in some practice settings, be asked to evaluate or comanage pregnant women with fetal arrhythmia.

Original languageEnglish (US)
Pages (from-to)31-37
Number of pages7
JournalCardiology in review
Volume30
Issue number1
DOIs
StatePublished - Jan 1 2022
Externally publishedYes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Fetal Supraventricular Tachycardia: What the Adult Cardiologist Needs to Know'. Together they form a unique fingerprint.

Cite this